LINC02085 Regulates Cell Growth and Inflammatory Response in Rheumatoid Arthritis by Regulating PI3K/ AKT Signaling Pathway

Jianting Wen
Anhui University of Traditional Chinese Medicine

Jian Liu (✉ liujianahzy@126.com)
Anhui University of Traditional Chinese Medicine - East Campus: Anhui University of Traditional Chinese Medicine
https://orcid.org/0000-0003-3101-7553

Xin Wang
Anhui University of Traditional Chinese Medicine - Meishan Road Campus: Anhui University of Traditional Chinese Medicine

Jie Wang
Anhui University of Traditional Chinese Medicine - Meishan Road Campus: Anhui University of Traditional Chinese Medicine

Research

Keywords: LINC02085, fibroblast-like synoviocytes, cell growth, rheumatoid arthritis

DOI: https://doi.org/10.21203/rs.3.rs-126642/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The present study explored the possible functions and the underlying mechanism of long Non-coding RNA LINC02085 in rheumatoid arthritis (RA).

Methods: Primary fibroblast-like synoviocytes (FLS) were separated from synovial tissues and was established cell lines, then cultured for subsequent cell experiments by transfecting different vectors. Rat with AA were injected with sh-LINC02085. The progression of AA was explored by measuring arthritis score and histologic analysis. ELISA analysis was employed to detect the levels of inflammatory cytokines. CCK8 assay, migration and invasion assays were used to evaluate the proliferation, migration and invasion abilities of cells, respectively. Besides, the levels of the the PI3K/AKT pathway-related proteins were measured by WB and IF.

Results: The expression level of LINC02085 was significant high in patients with RA, and positively associated with clinical indexes. We found that LINC02085 was upregulated in RA -FLS and TNF-α-stimulated. And overexpression of LINC02085 could promote proliferation, migration and invasion induced by TNF-α, through upregulating the levels of TNF-α and TNFAIP2 and promoting the activation of PI3K/AKT pathway. Whereas downexpression of LINC02085 received the opposite results. Knockdown of LINC02085 significantly ameliorated the progression of AA reflected by decreased arthritis score and cartilage destruction.

Conclusion: The present study revealed that LINC02085 could regulate cell growth and inflammatory response of RA-FLS by activating the PI3K/ AKT signaling pathway, subsequently playing important roles in promoting the occurrence and development of RA.

Background

Rheumatoid arthritis (RA), a chronic systemic disease, is featured with inflammatory synovitis, which can lead to destruction on bone and cartilage and even cause disability[1; 2]. The chronic and recurrent pain imposes a substantial burden on patients’ quality of life, and brings great mental impact and economic pressure to patients and their families[3; 4]. Fibroblast-like synoviocytes (FLSs) have been proven to be the main effector cells, which play a critical role in the initiation and regulation of immune responses[5; 6]. Tumor necrosis factor-α (TNF-α), the pro-inflammatory cytokine, critically promotes the progress of RA[7; 8]. Despite the development of various treatment strategies for RA, the management of RA is still a challenge, which suggesting the need for a deeper understanding of the mechanism of RA, especially at molecular level[9; 10].

A substantial portion of this “genomic dark matter” is long non-coding RNA (lncRNA), defined as ncRNA greater than ~200 nucleotides in length, accounting for 68% of RNA molecules[11; 12]. Recently, the functions of IncRNAs and their associations with human diseases have attracted much attention from researchers because increasing evidences indicated that IncRNAs play critical roles in the development of various autoimmune diseases, such as ankylosing spondylitis (AS)[13], osteoarthritis (OA) [14]and
systemic lupus erythematosus (SLE) [15] with the complete mechanism. LncRNAs can crosstalk with immune cells and mediate immunological and inflammatory response through phosphoinositide-3-kinase (PI3K) / protein kinase B (AKT) signaling pathway[16]. Recently, a number of studies indicated that a number of dysregulated lncRNAs contribute to the inflammatory response in RA[17]. Certain differentially expressed lncRNAs in RA have been reported to affect the disease activity[18]. In our previous study, many differentially expressed lncRNAs were screened out from a high-throughput sequencing analysis, including LINC02085[19]. Nevertheless, the precise role and mechanisms of LINC02085 in RA pathogenesis remain unclear, particularly regarding its role in regulating inflammation.

In the present research, we selected LINC02085 as the subject and investigated its levels in the PBMCs of patients with RA. Next, we performed cellular experiments to verify the possible mechanism and assess the effects of the abnormally expressed LINC02085 in inflammatory responses and cell biological processes of RA-FLS. In addition, PI3K/AKT signal pathway aspect was found to be active under the LINC02085 condition. Based on these encouraging results, we believe that the present study could further elucidate a theoretical basis for the underlying mechanism of LINC02085 in RA.

**Materials And Methods**

**Ethics Approval**

This study was approved by the Ethics Committee of the First Affiliated hospital of Anhui University of Traditional Chinese Medicine, and all patients signed a statement of informed consent.

**Subjects And Samples**

The present study recruited 30 patients with RA from May 2015 to July 2015. The inclusion criteria were (1) all the subjects fulfilled the 2010 American College of Rheumatology (ACR) criteria for the diagnosis of RA[20]; (2) complete clinical data of all patients were available. The exclusion criteria were (1) patients below the age of 18 years and older than 75 years were also excluded; (2) pregnant women, people with severe mental illness, people with liver and kidney function injury were excluded; (3) people for biologic agents treatment were excluded. In addition, 30 healthy participants served as healthy controls (HC).

**Observation Indexes**

Clinical indicators: sex, age, duration of disease, erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (CCP), immunoglobulins A (IGA), immunoglobulin G (IGG), immunoglobulin M (IGM), complement 3 (C3), and complement 4 (C4).

Self-perception of patients (SPP): Disease activity score (DAS28), Visual analog scale (VAS), Anxiety self-assessment scale (SAS), Depression self-assessment scale (SDS) scores.

**PBMC Collection And Total RNA Extraction**
Peripheral blood (5 ml) was collected from all subjects in vacuum blood tubes containing EDTA-K2. PBMCs were isolated by density gradient centrifugation (Histopaque-1077, Sigma). Total RNA was extracted from PBMCs using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol and stored at -80°C. The RNA concentration was determined with a NanoDrop (Thermo Scientific), and RNA integrity was assessed by agarose gel electrophoresis.

Cell Culture

Primary FLS were separated from synovial tissues. Briefly, synovial tissue samples were obtained from RA patients who had undergone joint replacement surgery, which was cut into small pieces and then minced and digested with 4 mg/mL collagenase type I (Sigma) for 1 h in Dulbecco's modified Eagle's medium (DMEM; Sangon Biotech, Shanghai, China) at 37 °C for 1 h. The cells were then digested using 0.25% trypsin. After centrifugation at 800g and further at 1000g, the RA-FLS was maintained in RPMI-1640 (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS), 100 mg/L streptomycin and 1×10^5 U/L penicillin. The separated RA-FLS were cultured to the third to sixth generations and were used for further study.

Cell Transfection

The coding sequence of LINC02085 was amplified and inserted into pcDNA3.1 (+) to produce the overexpressed vector of LINC02085 (pcDNA3.1-LINC02085). The silenced vectors si-LINC02085 and si-NC, and scrambled siRNA (si-NC) were obtained from GenePharma Co., Ltd. (Shanghai, China). The RA-FLS were transiently transfected with the above vectors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Next, the transfected RA-FLS were incubated for 24 h and the cells were treated with TNF-α (10 ng/mL) for 24 h.

Cell Counting Kit 8 (CCK-8) Assay

CCK-8 was utilized to determine the viability of both the treated and untreated RA-FLS. Transfected cells were placed in three replicates at a density of 3 × 10^4 cells per well in a 96-well plate with 100 µl of medium and incubated for 0, 24, 48, and 72 h after treatment with 10 ng/ml TNF-α. Then, the cells were incubated for 2 h in 10 µl of CCK-8 solution. Absorbance (optical density, OD) was assessed at 490 nm using an absorbance reader. The experiment was performed in triplicate.

Quantitative real-time PCR (RT-qPCR)

Total cellular RNA was extracted using TRizol reagent (Invitrogen, NY, USA). To measure the expression of LINC02085, cDNA was reversely transcribed from total RNA by Prime Script TM RT reagent Kit with gDNA Eraser (TaKaRa, Dalian, Liaoning, China). And then qPCR was performed using TB Green™ Premix Ex Taq™ (Tli RNaseH Plus) (TaKaRa, Shiga, Japan) according to the manufacturer's protocol. β-actin was used as an internal control. The primers were synthesized by Sangon Biotech. The primer sequences are listed in Table 1. The data were analyzed using the 2^−ΔΔct method.
Enzyme-linked Immunosorbent Assay (ELISA)

The supernatants of treated RA-FLS were collected and centrifuged at 1500×g for 10 min at 4 °C. The concentrations of TNF-α (Cat No. JYM0110Hu ) and TNFAIP2 (Cat No. JYM2468Hu ) in supernatants were determined using the corresponding enzyme-linked immunosorbent assay (ELISA) Kits (Sangon Biotech) according to the manufacturers instructions. The absorbance at 450 nm was read using a Microplate Reader (BioTek, USA). The concentrations of TNF-α and TNFAIP2 were calculated based on the standard curve.

Cell Migration Assay

After 48 h, RA-FLS were digested using 0.25% trypsin (Gibco; Thermo Fisher Scientific, Inc.). 3×10^4 RA-FLS were plated to the top chamber of transwell (24-well insert, pore size, 8 μm, Coring, USA) precoated with Matrigel (BD, Bioscience). Then, 600 μL of DMEM containing 10% FBS was added to the lower chamber. After 24 h of incubation at 37 °C, the RA-FLS in the upper chamber were carefully removed with cotton swabs, and cells in the lower chamber were washed with PBS. Afterwards, cells were fixed with 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet for 30 min. Positive stained cells were observed under a microscope (Olympus) and counted at four randomly selected fields.

Cell Invasion Assay

Transwell invasion assay was carried out following a similar procedure as the Transwell migration assay. In brief, wells in a 96-well plate were pre-coated with 5 μg of Matrigel (BD Matrigel matrix, Matrigel basement membrane matrix, Biosciences). Matrigel was diluted 1:5 with DMEM. RA-FLS were transfected for 48 h and suspended in 100 μL serum-free medium at a final concentration of 3 x 10^4 cells/ml were seeded in the upper well. Similarly, in each lower chamber, 600 ml of DMEM medium with 10% FBS was added. Microscopic visualization and cells counting were conducted as described with the migration assays.

Western Blotting (WB)

The RA-FLS were lysed by RIPA lysis buffer (Sangon Biotech), following which cytoplasmic and nuclear proteins were extracted from RA-FLS using a commercial kit (Pierce, Rockford, IL, USA). Each sample (25
mg protein) was prepared for electrophoresis running on 10% SDS/PAGE gel and then transferred onto PVDF membranes (Millipore). The membrane was then blocked in a 5% nonfat dry milk/Tris-buffered solution and incubated at 4 °C with primary antibody overnight: rabbit anti-human anti-p-PI3K (dilution, 1:1000; cat. No. ab182651), rabbit anti-human anti-p-AKT (dilution, 1:2000; cat. No. 4060s). The membrane was then washed in PBST for three times, and incubated with the horseradish peroxidase (HRP)-labeled goat anti-rabbit immunoglobulin G (IgG) secondary antibody (dilution, 1:20000, ab6721) at 37 °C for 1.5 h. Lastly, the proteins were detected by enhanced chemiluminescence (ECL, Millipore, USA). The densities of the bands were quantified by Image J Software (version 1.45, NIH, USA).

**Immunofluorescence Assay (IF)**

The RA-FLS were fixed with 4% paraformaldehyde at 48 h post transfection, washed three times with PBS and blocked with 2% BSA in PBS for 15 min. After blocking, cells were incubated with primary antibodies diluted in blocking buffer overnight at 4 °C. The RA-FLS were washed three times with PBS and incubated for 1 h with fluorophore-conjugated secondary antibodies (1:1000; Invitrogen) in blocking buffer. Cell nuclei were stained with DAPI (Invitrogen). Images were acquired using a Zeiss LSM710 confocal microscope.

**Induction of RA rat model and gene therapy**

Male SD rats (n=24, 280–300 g, 7-weeks-old) were purchased from the Center for Laboratory Animals of Anhui (license No.: SYXK 2017-0006, Hefei, China). They were kept under constant temperature (22 ± 2 °C), humidity (55%) and light/dark conditions (12/12 h). All the rats were allowed food and water ad libitum. All animal experiments were performed according to approved protocols by the Institutional Animal Care and Use Committee of the National Institutes of Health, USA. The adjuvant-induced arthritic (AA) rat model was established according to the protocol described in our previous study. Briefly, the AA model was induced in SD rats by subcutaneous injection into the right hind metatarsal footpad with 100 μL of Freund’s complete adjuvant (FCA, Sigma). The rat of normal control group were also subcutaneously injected the saline solution with the same dosage.

For evaluating the therapeutic effects of LINC02085, when arthritis symptoms were appeared, the rats were randomly and evenly allocated into four groups, six rats in each group: normal control (NC), model control (MC), MC with the treatment of blank plasmid (sh-NC), MC with the treatment of LINC02085 plasmid (sh-LINC02085). Lentivirus stocks expressing shRNA for LINC02085 at a concentration of 5x108 virus particles per millilitre were injected via tail vein rats from the 4th day after the first immunization. The sh-NC group were injected with sh-NC to serve as an internal control. Arthritis scores (0–4 for each paw; maximum possible score 16) were determined every 5 days. Serum was collected for erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), TNF-α and IL-6 measurement. PBMCs were obtained to detect LINC02085 expression. Hematoxylin and eosin (HE) staining of the sections was performed to observe morphological changes in the synovial tissue.

**Association Rule Mining (ARM)**
The clinical indexes rise was set to “T”, while the clinical indexes decline was set to “F”. The Aprior module of SPSS Clementine 11.1 software was used to analyze the correlation between observation clinical indexes. The most famous association rule is the Apriori algorithm, which aims to find out the relationship between items in a data set, also known as shopping blue analysis. In our data, each drug was treated as a variable[21]. The formulae were as follows:

\[
\text{support}(X\rightarrow Y) = \frac{\sigma(X \cup Y)}{N},
\]

\[
\text{confidence}(X\rightarrow Y) = \frac{\sigma(X \cup Y)}{\sigma(X)},
\]

\[
\text{lift}(X\rightarrow Y) = \frac{\text{confidence}(X\rightarrow Y)}{\sigma(Y)},
\]

where \(X\rightarrow Y\) is an association rule, \(X\) (left-hand side [LHS]) and \(Y\) (right-hand side [RHS]) represent the set of LINC02085, \(\sigma(X)\) is the frequency of itemset \(X\), \(X \cup Y\) is the union of itemset \(X\) and \(Y\), \(\sigma(X \cup Y)\) is the frequency with which itemset \(X\) and itemset \(Y\) appear together, \(\text{support}(X\rightarrow Y)\) is the frequency with which \(X\) and \(Y\) appear together, and \(\text{confidence}(X\rightarrow Y)\) is the probability that itemset \(Y\) appears in the presence of \(X\). The lift is the ratio of the probability of itemset \(Y\) appearing in the presence of \(X\) to the frequency of \(Y\). Support and confidence are often used to eliminate meaningless combinations; lift is the validity of the rules.

**Statistical Analysis**

Statistical analyses were performed with GraphPad Prism software 8.0 (GraphPad). Data are represented as the mean ± SD or median (interquartile ranges) and analyzed using Students t-test or one-way ANOVA. A Chi square test was used to compare categorical variables. Spearman correlation analysis was introduced to evaluate the correlations between the LINC02085 with the items of ESR, RF, CCP, DAS28, et al. Logistic regression analysis was used to identify the independent risk factors of LINC02085. A statistically significant difference was defined as \(p < 0.05\).

**Results**

**Characteristics of the Study Subjects**

An independent cohort consisting of 30 RA patients and 30 HC were enrolled in the validation set for evaluation of abnormal LINC02085. The characteristics of the study subjects are summarized in Tab 2. There were no significant differences between RA patients and HC regarding age or sex. However, patients with RA had higher ESR, CRP, RF, CCP, IGA, IGG, IGM, C4, C4, DAS28, VAS, SAS and SDS than those in HC (\(p < 0.05\); Tab 2).
Table 2 The general characteristics of RA patients

| Variables                     | RA(n=30)          | HC(n=30)          | Normal range |
|-------------------------------|-------------------|-------------------|--------------|
| Sex(M/F)                      | 3/27              | 3/27              | NA           |
| Age(year)                     | 45.73±10.88       | 45.63±10.96       | NA           |
| Duration of disease (year)    | 7.03±4.61         | NA                | NA           |
| ESR (mm/h)                    | 61.00(32.50, 82.25) | 3.91(2.96, 4.69)  | 2.0-6.0      |
| Hs-CRP (mg/L)                 | 41.02(18.79, 89.54) | 2.15(1.35, 2.90)  | 0.00-3.00    |
| RF (U/ml)                     | 117.71(44.90, 271.35) | 8.26(6.92, 10.45) | 0.0-14.0     |
| CCP (U/ml)                    | 97.65(32.15, 210.50) | 2.12(1.54, 2.89)  | <4.00        |
| IGA (g/L)                     | 2.77(2.31, 3.12)  | 2.48(1.82, 3.28)  | 0.70-4.06    |
| IGG (g/L)                     | 15.84(13.99, 17.02) | 12.06(9.19, 16.31) | 6.80-14.50  |
| IGM (g/L)                     | 1.78(1.51, 2.42)  | 1.81(1.14, 2.63)  | 0.34-2.14    |
| C3 (g/L)                      | 1.56(1.35, 1.76)  | 1.09(0.62, 1.32)  | 0.9-1.8      |
| C4 (g/L)                      | 0.38(0.27, 0.46)  | 0.38(0.27, 0.43)  | 0.1-0.4      |
| DAS28 score                   | 6.54(5.77, 7.47)  | NA                | <2.6         |
| VAS score                     | 7.00(6.00, 8.00)  | 3.78(3.06, 4.27)  | NA           |
| SAS score                     | 55.25(54.38, 62.50) | 82.86(77.75, 87.24) | NA          |
| SDS score                     | 55.00(51.25, 65.00) | 76.60(71.95, 80.48) | NA          |

ESR: Erythrocyte sedimentation rate, hs-CRP: high-sensitivity C-reactive protein, RF: rheumatoid factor, CCP: anti-cyclic citrullinated peptide antibody, IGA: immunoglobulin A, IGG: immunoglobulin G, IGM: immunoglobulin M, C3: complement 3, C4: complement 4, DAS: Disease Activity Score, VAS: Visual Analogy Scale, SAS: Anxiety Self-Assessment Scale, SDS: Depression Self-Assessment Scale.

a p > 0.05, b p < 0.01

The Expression of LINC02085 in PBMCs of RA Patients

To explore the levels of LINC02085 in patients with RA, RT-qPCR was performed and the results showed significantly higher levels of LINC02085 in patients with RA compared with HC (p < 0.01; Fig. 1A). To evaluate the diagnostic value of LINC02085, receiver operating characteristic (ROC) curve analysis was
performed. The AUC of LINC02085 was 0.8861 (95% CI 0.7958—0.9765), which suggested that LINC02085 had potential diagnostic value for RA patients (Fig. 1B).

Spearman Correlation Analysis of LINC02085 with Clinical Characteristics of RA Patients

In addition, Spearman correlation analysis showed that the expression level of LINC02085 levels in RA PBMCs positively correlated with age \((r = 0.6241, p = 0.0002; \text{Fig. 1A})\), ESR \((r = 0.6109, p = 0.0003; \text{Fig. 1B})\), CRP \((r = 0.5254, p = 0.0029; \text{Fig. 1C})\), RF \((r = 0.6521, p < 0.0001; \text{Fig. 1D})\), CCP \((r = 0.7882, p < 0.0001; \text{Fig. 1E})\) and DAS28 \((r = 0.8456, p < 0.0001; \text{Fig. 1F})\). All these findings revealed that the abnormal expression of LINC02085 could be involved in the biology of RA.

Association Rule Analysis of LINC02085 with Clinical Characteristics of RA Patients

Then we conducted an association rule analysis to determine the confidence, support, and lift value of LINC02085 and clinical characteristics of RA patients. The results are shown that the confidence and support value of LINC02085 and clinical characteristics both higher than 80%, and the degree of lift was more than 1 and \(p < 0.05\) through Aprior module analysis (Tab 3).

| Items (LHS RHS) | Support | Confidence | Lift | \(P\) value |
|----------------|---------|------------|------|-------------|
| \{LINC02085 ↑ \} \{ESR ↑ \} | 83.78% | 92.72% | 1.15 | \(p < 0.01\) |
| \{LINC02085 ↑ \} \{CRP ↑ \} | 83.85% | 91.43% | 1.04 | \(p < 0.01\) |
| \{LINC02085 ↑ \} \{RF ↑ \} | 81.35% | 91.83% | 1.04 | \(p < 0.01\) |
| \{LINC02085 ↑ \} \{IGA ↑ \} | 83.95% | 87.91% | 1.15 | \(p < 0.01\) |
| \{LINC02085 ↑ \} \{IGG ↑ \} | 87.07% | 87.55% | 1.15 | \(p < 0.01\) |
| \{LINC02085 ↑ \} \{C3 ↑ \} | 81.15% | 87.55% | 1.05 | \(p < 0.01\) |

Logistic Regression Analysis of LINC02085 with Clinical Characteristics of RA Patients

To assess risk factors for LINC02085, logistic regression analysis was carried out. Significant differences in LINC02085 was found between RA patients with ESR \((p = 0.023)\), RF \((p = 0.000)\), CCP \((p = 0.013)\) and DAS28 \((p = 0.002)\), indicating that ESR, CRP, RF and DAS28 were risk factors for LINC02085, the higher expression of ESR, CRP, RF and DAS28, the higher expression of LINC02085 (Fig. 3).

The Expression of LINC02085 in RA-FLS

To evaluate the expression level of LINC02085 in RA-FLS, we detected LINC02085 by RT-qPCR analysis in RA-FLS. A significant upregulation in the expression level of LINC02085 was observed in the RA-FLS were stimulated with TNF-α compared with RA-FLS (Fig. 4). Also, the efficiency of overexpression and knockdown was assessed by RT-qPCR. The results suggested that LINC02085 was significantly elevated by the transfection of LINC02085 overexpression vector, and the knockdown of LINC02085 resulted in significantly reduced LINC02085 expression (Fig. 4).

**Effects of LINC02085 Aberrant Expression on Cell Proliferation**

Furthermore, the cell viability of RA-FLS was remarkably increased by the TNF-α level relative to that in RA-FLS (Fig. 5). Consistently, TNF-α-induced cells with pc-DNA3.1 LINC02085 showed higher cell viability relative to the TNF-α-induced cells (Fig. 5). In addition, the cell viability was dramatically decreased in TNF-α-induced cells with si-LINC02085 relative to TNF-α-induced cells (Fig. 5).

**Effects of LINC02085 Aberrant Expression on Cell Migration and Invasion**

To explore the effects of LINC02085 on RA-FLS migration and invasion ability, we performed a migration assay and an invasion assay using Boyden chamber. Transwell migration and invasion assays showed that TNF-α increased the ability of the migration and invasion of RA-FLS significantly, overexpression of LINC02085 effectively increased the migration and invasion ability of the RA-FLS, while knockdown of LINC02085 inhibited the migration and invasion of the RA-FLS (Fig. 6A-B).

**Effects of LINC02085 Aberrant Expression on Inflammatory Cytokines**

The ELISA results revealed that TNF-α treatment enhanced the levels of TNF-α and TNFAIP2. Furthermore, TNF-α and TNFAIP2 levels were remarkably reduced when TNF-α-induced cells were transfected with si-LINC02085 compared with those in TNF-α-induced cells (Fig. 7A-B). Furthermore, TNF-α-induced cells with pcDNA3.1-LINC02085 showed higher TNF-α and TNFAIP2 levels than TNF-α-induced cells (Fig. 7A-B).

**Effects of LINC02085 Aberrant Expression PI3K/AKT Pathway**

To further find the possible correlation of LINC02085 abnormal expression and the pathway involved in RA, we performed experiments to detect the expression of PI3K/AKT pathway-related proteins. In relation to the untreated cells, the proteins expression of p-PI3K and p-AKT were significantly upregulated in TNF-α-induced cells (Fig. 8A-C). The TNF-α-induced cells transfected with pcDNA31.-LINC02085 showed dramatically enhanced relative protein expression of p-PI3K and p-AKT compared with those in TNF-α-induced cells (Fig. 8A-C), whereas the protein levels were significantly reversed in the TNF-α-induced cells transfected with si-LINC02085 compared with those in the TNF-α-induced cells (Fig. 8A-C). Similar results were also illustrated in the hippocampus by immunofluorescence analysis (Fig. 8E-F). These findings indicated that the PI3K/AKT signal pathway could be activated by the highly expressed LINC02085 in RA.
LINC02085 treatment suppressed synovial inflammation and joint damage

To determine whether LINC02085 plays a crucial pathogenic role in the progression of RA, the lentivirus of LINC02085 shRNA or control shRNA was locally injected into inflamed joints to knockdown the expression of LINC02085 in AA rat. As shown in Fig. 9A-B, we found that the arthritis index and paw swelling were significantly lower in the sh-LINC02085-treated group compared with that in the MC group. Our data from the RT-qPCR revealed that LINC02085 expression was significantly increased in MC group compared with NC group, while significantly decreased in sh-LINC02085 group (Fig. 9D). We also found that the serum level of ESR, CRP, RF, TNF-α and IL-6 were significantly decreased in the sh-LINC02085-treated group (Fig. 9E-I). To further assess the effect of LINC02085 on developed arthritis, a histopathological evaluation was performed. The results suggested that the pathological features of RA were obviously observed in the ankle joints of MC group including inflammatory cell infiltration, synovial hyperplasia, and cartilage destruction. In contrast, sh-LINC02085 significantly attenuated the above-described structural changes (Fig. 9C). Taken together, these findings indicated that knockdown LINC02085 suppressed arthritic progression with significant amelioration of joint damage.

Discussion

Expanding numbers of studies have documented that lncRNAs play critical roles in physiological and pathological responses in different human disease including RA[22; 23]. The current study firstly provided evidence that LINC02085 was overexpressed in PBMCs of patients with RA compared with the healthy participants. The LINC02085 levels in RA blood samples positively correlated with those of age, ESR, CRP, RF, CCP and DAS28. Additionally, there are high confidence, support and lift value between LINC02085 and clinical characteristics. Meanwhile, ESR, RF, CCP and DAS28 are independent risk factors for LINC02085. Further analysis showed that overexpression of LINC02085 promoted RA-FLS proliferation, migration and invasion ability, enhanced the inflammatory response by increasing the levels of TNF-α and TNFAIP2. Furthermore, upregulated LINC02085 remarkably increased the expression of p-PI3K and p-AKT. However, the opposite results were observed for LINC02085 knockdown. LINC02085 offers promising therapeutic strategy for RA patients.

An increasing number of studies have indicated that abnormal lncRNAs expression is involved in various immune-mediated diseases and serves an important role in regulating the inflammatory response and cell growth[24]. A study revealed that IncRNA PVT1 can regulate the proliferation and inflammatory responses of RA-FLS by targeting microRNA-145-5p[25]. Another additional study demonstrated that inhibiting role of LINC01197 in inflammation in RA through the microRNA-150/THBS2 axis[26]. The present study found the upregulation of LINC02085 in RA. A recent study further demonstrated that abnormal expression levels of IncRNA in RA closely related to the severity of symptoms[27; 28]. Similarly, our study revealed a positive correlation of LINC02085 levels with those of ESR, CRP, RF and DAS28, indicating LINC02085 levels were associated with the severity of RA. In addition, the current study found that upregulated LINC02085 enhanced proliferation, migration, and invasion ability of cells. RA-FLS proliferation, migration and invasion are the most important pathologic features of RA, which together
with inflammatory responses affect and promote each other, and involved in the pathogenesis of RA[29]. Our results suggested that overexpression of LINC02085 could promote RA-FLS cell growth. The previous studies have confirmed that RA-FLS could secrete various kinds of inflammatory cytokines, thereby directly aggravating the inflammatory response[30; 31]. Our findings showed that inflammatory cytokines of TNF-α and TNFAIP2 were dramatically increased in TNF-α-treated RA-FLS transfected with pcDNA3.1-LINC02085; however, the levels were reversed when LINC02085 was suppressed, implying that the reduction in LINC02085 expression could suppress cell inflammatory response. Thus, we speculated that LINC02085 might participate in the occurrence and development of RA by involving in cell growth and inflammatory response of FLS. Furthermore, the in vivo results showed that knockdown of LINC02085 has an anti-inflammatory effect that can alleviate the progression of arthritis in AA rat, suggesting that LINC02085 knockdown could be potentially applied in the treatment of RA.

To further find out the potential correlation and mechanism of LINC02085 at the level of the signal pathway in RA-FLS, we selected the PI3K/AKT signaling pathway based on the following aspects. First, the PI3K/AKT signaling pathway has been showed to anticipate in the pathogenesis of RA and may serve as an important target in RA therapies. For example, Huang et al. demonstrated that miR-26a-5p enhances cells proliferation, invasion, and apoptosis resistance of FLS in RA by regulating PTEN/PI3K/AKT pathway[32]. Similarly, Li reported that cinnamaldehyde attenuates the progression of RA through down-regulation of PI3K/AKT signaling pathway[33]. Second, IncRNA THRIL mediates cell growth and inflammatory response of FLS by activating PI3K/AKT signals in RA[16]. Based on these findings, we speculated the existence of a possible direct or indirect regulatory correlation between LINC02085 and the PI3K/ AKT pathway. Our findings showed that overexpression and knockdown of LINC02085 retrained the protein expression of p-PI3K and p-AKT, which verified our speculation. It can be said that PI3K/AKT not merely involved in immune-mediated responses, but also mediates important signaling transduction in cell biological progression. The activation of p-PI3K could first induce the downstream p-AKT, followed by inducing high expression levels of inflammatory factors TNF-α and TNFAIP2, subsequently increased proliferation, migration and invasion ability. This study concluded that LINC02085 could induce the PI3K/ AKT signaling pathway activation. Therefore, we speculated that LINC02085 mediates cell growth and inflammatory response of RA-FLS by activating PI3K/AKT signals.

In summary, the present study revealed that LINC02085 was highly expressed in RA and its abnormal expression could regulate the cell growth and inflammatory response of RA-FLS by activating the PI3K/AKT signaling pathway through affecting proliferation, migration and invasion ability of RA-FLS, thereby promoting the occurrence and development of RA. Additionally, the model of sponge which IncRNA interacts with other miRNA may be one of the important regulatory mechanisms in cells. Based on the the current findings, we have great interests in this research, our research team is attempting to explore the possible ceRNA molecular mechanism of LINC02085 in RA in our future work.

**Conclusion**
In summary, the expression level of LINC02085 was significantly increased in RA. LINC02085 can influence RA-FLS proliferation, invasion and migration, regulates inflammatory responses, which illustrates the pivotal role of LINC02085 in RA pathogenesis. Clinical studies have shown that there is a significant association between LINC02085 and other clinical parameters. In vitro assays suggested that LINC02085 mediates cell biological functions and inflammatory response of RA-FLS by activating PI3K/AKT signals. In vivo experiment was conducted to further confirm that knockdown of LINC02085 has an anti-inflammatory effect that can alleviate the progression of arthritis in AA rat.

**Abbreviations**

PBMCs: Peripheral blood mononuclear cells

FLS: Fibroblast-like synoviocytes

RA: Rheumatoid arthritis

TNF-α: Tumor necrosis factor-α

LncRNA: Long non-coding RNA

PI3K: phosphoinositide-3-kinase

AKT: protein kinase B

AS: Ankylosing spondylitis

OA: Osteoarthritis

SLE: Systemic lupus erythematosus

ESR: erythrocyte sedimentation rate

Hs-CRP: high-sensitivity C-reactive protein

RF: rheumatoid factor

CCP: anti-cyclic citrullinated peptide antibody

IGA: Immunoglobulins A

IGG: Immunoglobulin G

IGM: Immunoglobulin M

C3: Complement 3
C4: Complement 4
SPP: Self-perception of patients
DAS28: Disease activity score
VAS: Visual analog scale
SAS: Anxiety self-assessment Scale
SDS: Depression self-assessment scale
CCK-8: Cell Counting Kit 8
RT-qPCR: Quantitative real-time PCR
ELISA: Enzyme-linked immunosorbent assay
WB: Western blotting
IF: Immunofluorescence assay
ARM: Association rule mining.

Declarations

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledges
Not applicable.

Funding
This work was supported by Grants from Ministry of Science and Technology National Key Research and Development Program Chinese Medicine Modernization Research Key Project (2018YFC1705204); National Nature Fund Program (81973655); National Natural Science Foundation of China (82074373); Open Foundation of Key Laboratory of Xin’an Medical Ministry of Anhui University of Traditional Chinese Medicine (No.2020xayx10); The Key Research and Development Program Foreign Science and Technology Cooperation Project of Anhui (201904b11020011); Anhui Provincial Quality Engineering Teaching and Research Project (2018jyxm1068); Anhui Famous Traditional Chinese Medicine Liu Jian Studio Construction Project (Traditional Chinese Medicine Development Secret [2018] No. 11); National Key Innovative Talents Training Project of Traditional Chinese Medicine (National Education Letter of
Author information

Affiliations

Anhui University of Traditional Chinese Medicine, Hefei 230031, Anhui Province, China

Jian Liu

Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230038, Anhui Province, China

Jianting Wen, Xin Wang & Jie Wang

Institute of Rheumatology, Anhui College of traditional Chinese Medicine, Hefei 230038, Anhui Province, China

Jian Liu & Jianting Wen

Contributions

WJT and LJ contributed to the study design. WJT contributed to data analysis, wrote the first draft, and revised the manuscript. WX and WJ contributed to the specimen and data collection. LJ supervised the project and contributed to the manuscript revision. All authors reviewed and accepted the content of the final manuscript.

Corresponding author

Correspondence to Jian Liu.

Ethics declarations

Ethics approval

This study was approved by the Ethics Committee of the First Affiliated hospital of Anhui University of Traditional Chinese Medicine, and all patients signed a statement of informed consent.

Consent for publication

Not applicable.

Competing interests
The authors declare no conflict of interest.

References

1. D. Hammaker, and G.J.C.o.i.r. Firestein, Epigenetics of inflammatory arthritis. 30 (2018) 188-196.
2. A. Catrina, V. Joshua, L. Klareskog, and V.J.I.r. Malmström, Mechanisms involved in triggering rheumatoid arthritis. 269 (2016) 162-74.
3. M. Lwin, L. Serhal, C. Holroyd, C.J.R. Edwards, and therapy, Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review. 7 (2020) 457-471.
4. B. Bai, M. Chen, L. Fu, H. Liu, L. Jin, T. Wei, F.J.H. Xin, and q.o.l. outcomes, Quality of life and influencing factors of patients with rheumatoid arthritis in Northeast China. 18 (2020) 119.
5. B. Bartok, and G.J.I.r. Firestein, Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. 233 (2010) 233-55.
6. N. Bottini, and G.S.J.N.R.R. Firestein, Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. 9 (2013) 24-33.
7. C. Hou, D. Wang, and L.J.M.m.r. Zhang, MicroRNA-34a-3p inhibits proliferation of rheumatoid arthritis fibroblast-like synoviocytes. 20 (2019) 2563-2570.
8. J. Qiang, T. Lv, Z. Wu, and X.J.B.r. Yang, Down-regulation of microRNA-142-3p inhibits the aggressive phenotypes of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting nuclear factor-κB signaling. 39 (2019).
9. M. Koenders, and W.J.T.i.p.s. van den Berg, Novel therapeutic targets in rheumatoid arthritis. 36 (2015) 189-95.
10. A. Deviatkin, Y. Vakulenko, L. Akhmadishina, V. Tarasov, M. Beloukhova, A. Zamyatnin, and A.J.B. Lukashev, Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy. 8 (2020).
11. M. Guttmann, I. Amit, M. Garber, C. French, M.F. Lin, D. Feldser, M. Huarte, O. Zuk, B.W. Carey, and J.P.J.N. Cassady, Chromatin Signature Reveals over a Thousand Highly Conserved Large Non-Coding Rnas in Mammals. 458 (2009) 223-227.
12. J. Heward, and M.J.T.i.i. Lindsay, Long non-coding RNAs in the regulation of the immune response. 35 (2014) 408-19.
13. Y. Li, S. Zhang, C. Zhang, M.J.M. Wang, and c. biochemistry, LncRNA MEG3 inhibits the inflammatory response of ankylosing spondylitis by targeting miR-146a. 466 (2020) 17-24.
14. C. Chen, and Y.J.I.i. Xu, Long noncoding RNA LINC00671 exacerbates osteoarthritis by promoting ONECUT2-mediated Smurf2 expression and extracellular matrix degradation. (2020) 106846.
15. Q. Liu, Y. Deng, C. Li, H. Xie, Q. Liu, S. Ming, D. Wu, and F.J.I.I. Luo, LncRNA GAS5 suppresses CD4 T cell activation by upregulating E4BP4 via inhibiting miR-92a-3p in systemic lupus erythematosus. 227 (2020) 41-47.
16. Y. Liang, H. Li, X. Gong, and C.J.I. Ding, Long Non-coding RNA THRIL Mediates Cell Growth and Inflammatory Response of Fibroblast-Like Synoviocytes by Activating PI3K/AKT Signals in...
17. Z. Li, and T.J.R.b. Rana, Decoding the noncoding: prospective of IncRNA-mediated innate immune regulation. 11 (2014) 979-85.

18. T. Yue, X. Fan, Z. Zhang, Z. Liu, M. Guo, F. Bai, X. Gong, C. Gao, and L.J.A.j.o.t.r. Xiao, Downregulation of IncRNA ITSN1-2 correlates with decreased disease risk and activity of rheumatoid arthritis (RA), and reduces RA fibroblast-like synoviocytes proliferation and inflammation via inhibiting NOD2/RIP2 signaling pathway. 11 (2019) 4650-4666.

19. J. Wen, J. Liu, B. Wang, H. Jiang, L. Wan, L. Xin, Y. Sun, Y. Sun, Y. Zhang, X. Du, X. Wang, and J.J.F.i.m. Wang, Prediction of Self-Perception of Patient in Rheumatoid Arthritis With the Key RNAs Expression Profiles. 7 (2020) 567.

20. A. D, N. T, S. AJ, F. J, F. DT, B. CO, B. NS, B. GR, B. VP, C. MD, C. B, C. KH, D. M, E. P, F. G, H. JM, H. K, H. TW, K. A, K. J, K. TK, L. T, M. P, M. HA, M. LW, N. RL, P. T, S. JS, S.-B. E, S. D, T. PP, U. KS, V. J, W. F, H.G.J. Arthritis, and rheumatism, 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. 62 (2010) 2569-81.

21. J. Xie, N. Wang, R. Ding, J. Guo, L. Xin, and J.J.I.J.o.P.R. Liu, Association learning of Chinese herbal medicines and disease treatment efficacy. (2018) 1-20.

22. M. Lao, and H.J.C.m.j. Xu, Involvement of long non-coding RNAs in the pathogenesis of rheumatoid arthritis. 133 (2020) 941-950.

23. J. Wang, S. Yan, J. Yang, H. Lu, D. Xu, and Z.J.F.i.i. Wang, Non-coding RNAs in Rheumatoid Arthritis: From Bench to Bedside. 10 (2019) 3129.

24. S. Yan, P. Wang, J. Wang, J. Yang, H. Lu, C. Jin, M. Cheng, and D.J.F.i.i. Xu, Long Non-coding RNA HIX003209 Promotes Inflammation by Sponging miR-6089 via TLR4/NF-κB Signaling Pathway in Rheumatoid Arthritis. 10 (2019) 2218.

25. J. Tang, S. Yi, and Y.J.H.c. Liu, Long non-coding RNA PVT1 can regulate the proliferation and inflammatory responses of rheumatoid arthritis fibroblast-like synoviocytes by targeting microRNA-145-5p. 33 (2020) 1081-1090.

26. F. Zhao, J. Dong, J. Guo, and L.J.E.c.r. Bi, Inhibiting role of long non-coding RNA LINC01197 in inflammation in rheumatoid arthritis through the microRNA-150/THBS2 axis. 394 (2020) 112136.

27. L. Sun, J. Tu, C. Liu, A. Pan, X. Xia, and X.J.I. Chen, Analysis of IncRNA expression profiles by sequencing reveals that Inc-AL928768.3 and Inc-AC091493.1 are novel biomarkers for disease risk and activity of rheumatoid arthritis. 28 (2020) 437-450.

28. J. Wen, J. Liu, H. Jiang, L. Wan, L. Xin, Y. Sun, P. Zhang, Y. Sun, Y. Zhang, X. Du, X. Wang, and J.J.F.o.b. Wang, IncRNA expression profiles related to apoptosis and autophagy in peripheral blood mononuclear cells of patients with rheumatoid arthritis. (2020).

29. S. Zhong, Q. Ouyang, D. Zhu, Q. Huang, J. Zhao, M. Fan, Y. Cai, and M.J.M.i. Yang, Hsa_circ_0088036 promotes the proliferation and migration of fibroblast-like synoviocytes by sponging miR-140-3p and upregulating SIRT 1 expression in rheumatoid arthritis. 125 (2020) 131-139.
30. W.J.A. Arend, and rheumatism, Physiology of cytokine pathways in rheumatoid arthritis. 45 (2001) 101-6.

31. E. Choy, and G.J.T.N.E.j.o.m. Panayi, Cytokine pathways and joint inflammation in rheumatoid arthritis. 344 (2001) 907-16.

32. Z. Huang, S. Xing, M. Liu, W. Deng, Y. Wang, Z. Huang, Y. Huang, X. Huang, C. Wu, X. Guo, X. Pan, J. Jiang, F. Feng, and T.J.B.r. Li, MiR-26a-5p enhances cells proliferation, invasion, and apoptosis resistance of fibroblast-like synoviocytes in rheumatoid arthritis by regulating PTEN/PI3K/AKT pathway. 39 (2019).

33. X. Li, and Y.J.I. Wang, Cinnamaldehyde Attenuates the Progression of Rheumatoid Arthritis through Down-Regulation of PI3K/AKT Signaling Pathway. 43 (2020) 1729-1741.